Literature DB >> 26168647

[ISRAELI GUIDELINES FOR THE TREATMENT OF HYPERLIPIDEMIA - 2014 UPDATE].

Rafael Bitzur, Yoseph Rozenman, Shlomo Vinker, Dror Dikerl, Joseph Shemesh, Amnon Lahad, Dov Gavishl, Dror Harats, Hilla KnobLer.   

Abstract

Atherosclerosis is one of the leading causes of morbidity and mortality in the world, including in Israel. This document updates the clinical recommendations of the Israeli medical societies (The Society for Research, Prevention and Treatment of Atherosclerosis, The Israel Heart Society, The Israel Association of Family Physicians, The Israel Society of Internal Medicine) from 2012. The need for an update stems from new studies and from the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These recommendations take into account the guidelines of leading medical organizations in the world, as well as the specific circumstances and needs of the medical system in Israel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26168647

Source DB:  PubMed          Journal:  Harefuah        ISSN: 0017-7768


  1 in total

1.  Cessation of Bezafibrate in patients with chronic kidney disease improves renal function.

Authors:  Boris Zingerman; Danny Ziv; Netta Feder Krengel; Asher Korzets; Ilan Matok
Journal:  Sci Rep       Date:  2020-11-13       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.